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AbstrACt
background Vulvar high- grade squamous intraepithelial 
lesion (vHSIL) is predominantly induced by high- 
risk human papilloma virus type 16 (HPV16). In two 
independent trials, therapeutic vaccination against the 
HPV16 E6 and E7 oncoproteins resulted in objective 
partial and complete responses (PRs/CRs) in half of the 
patients with HPV16+ vHSIL at 12- month follow- up. Here, 
the prevaccination and postvaccination vHSIL immune 
microenvironment in relation to the vaccine- induced 
clinical response was investigated.
Methods Two novel seven- color multiplex 
immunofluorescence panels to identify T cells (CD3, 
CD8, Foxp3, Tim3, Tbet, PD-1, DAPI) and myeloid cells 
(CD14, CD33, CD68, CD163, CD11c, PD- L1, DAPI) 
were designed and fully optimized for formalin- fixed 
paraffin- embedded tissue. 29 prevaccination and 24 
postvaccination biopsies of patients with vHSIL, and 27 
healthy vulva excisions, were stained, scanned with the 
Vectra multispectral imaging system, and automatically 
phenotyped and counted using inForm advanced image 
analysis software.
results Healthy vulvar tissue is strongly infiltrated by 
CD4 and CD8 T cells expressing Tbet and/or PD-1 and 
CD14+HLA- DR+ inflammatory myeloid cells. The presence 
of such a coordinated pre- existing proinflammatory 
microenvironment in HPV16+ vHSIL is associated with CR 
after vaccination. In partial responders, a disconnection 
between T cell and CD14+ myeloid cell infiltration was 
observed, whereas clinical non- responders displayed 
overall lower immune cell infiltration. Vaccination improved 
the coordination of local immunity, reflected by increased 
numbers of CD4+Tbet+ T cells and HLA- DR+CD14+ 
expressing myeloid cells in patients with a PR or CR, but 
not in patients with no response. CD8+ T cell infiltration 
was not increased after vaccination.
Conclusion A prevaccination inflamed type 1 immune 
contexture is required for stronger vaccine- induced 
immune infiltration and is associated with better clinical 
response. Therapeutic vaccination did not overtly increase 
immune infiltration of cold lesions.
IntroduCtIon
The immune system is key to the control of 
tumor outgrowth. A dense infiltration with 
type 1 CD4+ and CD8+ T cells in the tumor 
microenvironment (TME) is prognostic 
for longer survival and associated with a 
favorable response to therapy in many but 
not all cancers.1 2 Several effective strate-
gies, including adoptive cell transfer3 4 and 
immune checkpoint blockade,5 6 demon-
strated the power of immunotherapy in 
cancer, making it one of the pillars of 
modern cancer therapy in the clinic. With 
the widespread testing of these immuno-
therapies, it has become clear that their 
success builds on the presence of pre- 
existing tumor- infiltrating T cells, since 
both their absence and their incapability 
to infiltrate the tumor cell nests are asso-
ciated with lack of response after immuno-
therapy.7 8 Hence, for those patients, there 
is a need for treatment modalities that 
can stimulate tumor- reactive T cell immu-
nity and/or promote their infiltration into 
tumors. Here, cancer vaccines come into 
play, since they can increase the magnitude 
and width of the tumor- reactive T cell pool 
by stimulating both the naive T cell reper-
toire and the existing tumor- specific T cell 
population. In a recent review, at least 18 
trials were identified to report regression of 
premalignant lesions or tumors after vacci-
nation with a series of different antigens 
over a spectrum of different solid tumors. 
In general, patients with a clinical response 
showed a robust or more active type 1 T cell 
response.9 In view of the fact that cancer 
immunity is influenced by a complex set of 
host, tumor and environmental factors10 11 it 
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was no surprise that vaccine- induced tumor regression 
was only observed in a few patients per trial.9
About 20% of human cancers are induced by viruses.12 
Human papillomavirus type 16 (HPV16) is a high- risk 
DNA virus which causes anogenital and oropharyngeal 
(pre- )cancers. To increase T cell reactivity against HPV16 
caused diseases, two DNA vaccines and one synthetic long 
peptide (SLP) vaccine have been developed to harness the 
immune system against the HPV16- encoded oncoproteins 
E6 and E7.13–16 Immunization with these vaccines resulted 
in the induction of potent CD4+ T helper type 1 (Th1) 
responses and CD8+ cytotoxic T cell responses in patients 
with HPV16- induced precancerous cervical lesions15–18 
and precancerous vulvar lesions (vulvar high- grade squa-
mous intraepithelial lesion (vHSIL)).19–21 Importantly, 
these vaccines were able to induce partial and complete 
regression of the lesions in a substantial number of vacci-
nated patients.19–22 More recently ISA101, an HPV16 SLP 
vaccine, showed strong biological signs of clinical activity 
in patients with either HPV16- positive oropharyngeal or 
cervical cancer.23 24 The HPV- specific T cell response after 
vaccination, as measured in the blood of patients, was 
strongly correlated to clinical outcome.19–22 24 25 Despite 
these correlations, there are still a number of patients 
who, based on their vaccine- induced immune response, 
were expected to show a clinical response but failed to 
do so. There may be a multitude of reasons for this, but 
inspired by the studies showing that checkpoint blockade 
is specifically successful in patients with pre- existing T cell 
inflamed tumors,10 11 we hypothesized that this may also 
hold true for therapeutic cancer vaccination.
In order to address this question, we studied a group of 
patients treated with ISA101, about 50% of whom showed 
an objective regression of their HPV16- induced vHSIL.21 
Based on our previous studies of the TME in vHSIL, 
demonstrating the impact of different types of immune 
cells on the recurrence rate of vHSIL,26 27 two anti-
body panels for studying T cells and myeloid cells were 
designed and fully optimized for multispectral immuno-
fluorescence imaging, hereby enabling unprecedented 
in- depth characterization of the immune composition in 
the TME of vHSIL biopsies before and after vaccination, 
and in healthy vulvar tissue for comparison. Our data 
revealed that complete responders (CR) to vaccination 
had a strong and coordinated pre- existing infiltration 
with type 1 T helper cells and inflammatory (CD14+) 
myeloid cells, similar to what was found in healthy 
vulvar tissue. In contrast, clinical non- responders (NR) 
displayed an intrinsic incapacity to attract immune cells 
as they displayed much lower overall infiltration before 
vaccination and this was not increased after vaccination.
MAterIAls And Methods
Patient materials
Prevaccination and postvaccination formalin- fixed 
paraffin- embedded (FFPE) biopsies of 29 women of ≥18 
years old with histologically confirmed HPV16 +vHSIL 
were taken. These women participated in a phase I/II 
therapeutic HPV16 SLP vaccination trial with ISA101.21 
The ISA101 vaccine was injected subcutaneously and 
consists of 13 SLPs covering the entire amino acid 
sequence of HPV16 oncoproteins E6 and E7, dissolved in 
dimethylsulfoxide in 20 mM of phosphate- buffered saline 
and emulsified with Montanide adjuvant (ISA-51 Seppic). 
Clinical efficacy assessments in the trial were performed 
at 3 and 12 months after the fourth and last vaccination. 
The patients were grouped into the best clinical response 
at 12 months after vaccination without additional treat-
ment: CR when the lesion completely disappeared, partial 
responders (PR) when≥50% of the total lesion area had 
disappeared, and NR when<50% of the lesion had disap-
peared. The presence of HPV16 DNA in the lesion was 
determined by HPV16 PCR analysis. Furthermore, FFPE 
healthy HPV- negative vulvar tissue from 27 anonymous 
women who underwent labia reduction surgery was 
included. All patients gave written informed consent.
Multiplex immunofluorescence imaging
The specificity of each primary antibody was first assessed 
with immunohistochemistry, tonsil slides served as posi-
tive and negative control. After selection of the best 
primary antibodies, the immunodetection conditions for 
each marker in seven color immunofluorescence were 
optimized. Dim markers were tyramide signal ampli-
fied with Opal to enable their detection by fluorescence 
microscopy, and primary antibodies with clashing species 
and isotypes in the panel were directly labeled with fluo-
rochromes or detected with species/isotype- specific 
antibodies.28 A complete overview of the design of the T 
cell panel and myeloid cell panel is presented in online 
supplementary files 1 and 2, respectively. In the seven 
color immunofluorescent procedure, 4 μm FFPE tissue 
sections were deparaffinized, endogenous peroxidase 
was blocked with hydrogen peroxide, and heat- induced 
epitope retrieval was performed with citrate (10 mM, pH 
6.0) in the T cell panel and with tris- EDTA (10 mM/1 mM, 
pH 9.0) in the myeloid cell panel. Non- specific binding 
sites were blocked with SuperBlock (ThermoFisher 
Scientific). First, the antibodies detected by Opal were 
applied and subjected to the recommended tyramide 
signal amplification protocol, followed by the unconju-
gated antibodies which were incubated overnight. On the 
second day, after detection of the previous with respective 
fluorescently labeled secondary antibodies, the directly 
labeled primary antibodies were incubated for 5 hours 
and, lastly, DAPI was applied as nuclear counterstain.28
Quantification of immune cells in the tMe
Immunofluorescence images were acquired with the 
Vectra V.3.0.5 multispectral imaging microscope (Perki-
nElmer) at 20× magnification and exposure times 
were set to avoid spectral overlap. Immune cells in the 
TME were automatically phenotyped and counted with 
inForm V.2.4 image analysis software (PerkinElmer), 
after manual training and validation of procedures. The 
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software was trained to segment epithelial and stromal 
fractions, segment DAPI +nucleated cells, and to assign 
a phenotype to each cell (online supplementary file 3a). 
All images were visually inspected on accurateness in 
segmenting tissue and phenotyping cells, and if errors 
were detected, the training was further optimized. Given 
the multitude of possible coexpressed markers, each 
seven color panel was divided into multiple subanalyses 
(online supplementary file 3b) to preclude the exclusion 
of relevant phenotypes, after which the phenotypes of 
the different subanalyses were merged per cell based on 
X,Y- positions to obtain the full seven marker expression 
profile of each cell. Immune cell counts were normal-
ized for tissue size (cells/mm2 epithelium and cells/mm2 
stroma). After merging all subanalyses, a threshold of a 
median cell count ≥10 cells/mm2 was applied to enable 
the analysis of relevant phenotypes.
statistical analysis
Statistical data analysis was performed with SPSS V.25.0 
(IBM Corporation). Immune counts of two groups were 
compared with the non- parametric Mann- Whitney U 
test. Pearson correlation was used to study correlations 
between the T cell infiltrate and the myeloid cell infiltrate 
in each group (clinical NR, PR, CR and healthy donor 
vulva). Two sided p values<0.05 were marked as signifi-
cant. GraphPad Prism V.8.0.1 (GraphPad Software) was 
used to create graphs.
results
healthy vulvar tissue is predominantly infiltrated by type 1 
activated t cells and inflammatory macrophages
Correct interpretation of the immune infiltration in 
precancerous vulvar lesions requires a profound under-
standing of the immune microenvironment in healthy 
vulvar tissue. In- depth characterization of the immune 
infiltrate was performed with two panels of antibodies to 
identify different subsets of T cells and myeloid cells in the 
epithelium and stroma, using multispectral immunofluo-
rescence imaging (figure 1A,B and online supplementary 
file 4). Analysis of 27 healthy HPV- negative vulvar tissues 
revealed that normal vulvar tissue is strongly infiltrated 
with T cells and myeloid cells, although at variable levels 
between individuals (figure 2A and online supplementary 
file 5). The intraepithelial infiltrate was dominated by 
type 1 Th cells (CD3+CD8−Foxp3−) expressing Tbet and 
a smaller fraction of which also expressed PD-1 as well 
as by inflammatory myeloid cells (CD14+ cells). A similar 
pattern was observed in healthy vulvar stroma; however, 
here also high numbers of M1 (CD68+CD163−) and 
M2 (CD68+CD163+) macrophages were found and the 
number of inflammatory myeloid cells (CD14+) super-
seded any other immune cell count by far. These data 
suggest that healthy vulvar tissue is a highly inflamma-
tory microenvironment comprising many type 1 (Tbet+) 
and activated (PD-1+) T lymphocytes and inflammatory 
macrophages.
strong variations in the lymphoid and myeloid immune 
infiltration of prevaccination vhsIl
We were able to include 29 of the 34 vaccinated patients 
with vHSIL21 for the current analysis (table 1). Two patients 
could not be included due to unavailability of FFPE tissue 
and three due to unknown response 12 months after 
vaccination. Analyses of the multispectral immunofluo-
rescence imaging for T cells and myeloid cells revealed 
that despite the same aetiology, the 29 patients with vHSIL 
formed a heterogeneous group as the counts of immune 
cells infiltrating the epithelium and stroma strongly 
differed per patient (figure 2B and online supplementary 
file 6). The overall pattern of intraepithelial and stromal 
immune cell infiltration resembled that found in healthy 
tissue. However, while 55% of the healthy vulvar tissue- 
infiltrating CD14+ myeloid cells expressed HLA- DR, this 
was only 26% in the vHSIL group (online supplementary 
file 7).
The patients with vHSIL were grouped according to 
their best clinical response obtained without additional 
treatment during the 12- month follow- up, into CR (n=7), 
PR (n=10) or NR (n=12). Plots of the data according 
to clinical outcome revealed a stepwise increase in the 
median number of intraepithelial and stromal CD8+ T 
cells, CD4+ (CD3+CD8−Foxp3−) Tbet+ Th cells and CD14+ 
inflammatory myeloid cells as clinical outcome improved, 
while that of Tregs stepwise decreased (figure 3A and 
online supplementary file 6). In order to ensure that the 
CD3+CD8− T cells were indeed CD4+ T cells, we analyzed 
a subset of patients with NR, PR and CR for the expres-
sion of CD3+, CD4+ and CD8+, confirming that on average 
99% of the CD3+CD8− T cells were CD4+ T cells (online 
supplementary file 8). Interestingly, the immune infil-
tration of prevaccination vHSIL in the CR group most 
closely resembled that of healthy vulvar tissue, whereas 
this was the opposite for the NR group.
Coordinated high infiltration with Cd4 and Cd8 type 1 t 
cells and inflammatory myeloid cells identifies the Cr to 
therapeutic vaccination
To gain a better insight in the coordination of the local 
immune response, we plotted the correlation between the 
absolute intraepithelial and stromal immune cell counts 
for the PR, CR and healthy donor tissues (figure 4), and 
not for the NR group as this would be uninformative due 
to the overall low cell counts. This analysis shows that 
there are strong correlations between the number of 
infiltrating CD8+ T cells and Th cells, as well as between 
the different types of myeloid cells; within a tissue 
segment (epithelium or stroma) and between both tissue 
segments in healthy vulva and in CR (figure 4). Impor-
tantly, there also is a strong correlation between the 
number of myeloid cells and CD8+ T cells (healthy, CR) 
and Th1 cells (CR), suggesting a coordinated immune 
infiltration of T cells and myeloid cells in both healthy 
vulvar tissue and in vHSIL of patients who will respond 
well to therapeutic vaccination. In contrast, there is no 
or a negative correlation between the vHSIL- infiltrating 
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Figure 1 Multiplex immunofluorescence staining to detect T cells and myeloid cells. Two multiplex panels were developed to 
detect T cells and myeloid cells in vulvar tissue. (A) The expression of each of the seven markers for T cells showing CD3, CD8, 
FoxP3, Tbet, Tim3, PD-1 and DAPI as well as a figure showing all seven markers simultaneously. Arrows indicate examples of 
analyzed phenotypes. (B) The expression of each of the seven markers for myeloid cells showing CD33, CD68, CD163, PD- L1, 
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Figure 2 Healthy vulvar tissue is infiltrated by activated type 1 T cells and several types of myeloid cells while the vulvar high- 
grade squamous intraepithelial lesion (vHSIL) immune infiltrate is highly heterogenic among different patients. The numbers of 
intraepithelial and stroma- infiltrating T cell and myeloid cell subtypes, of which the median cell count exceeded the threshold 
of ≥10 cells/mm2, are presented as cells/mm2 for (A) human papillomavirus- negative healthy vulva (n=27) and (B) vHSIL (n=29) 
before vaccination. Each dot represents an individual sample, the horizontal bars indicate the median cell counts, and the 
vertical bars are the 95% CIs.
T cells and myeloid cells in patients with a therapeutic 
vaccine- induced PR (figure 4), suggesting that either T 
cells or myeloid cells are under- represented in the prevac-
cination vHSIL immune microenvironment of patients 
with PR.
therapeutic vaccination does not overcome a ‘cold’ low-
infiltrated immune microenvironment
Three months post vaccination, all patients with vHSIL 
were rebiopsied, except for three patients with CR whom 
already reached complete response at 3- month follow- up, 
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Table 1 Patient characteristics prevaccination and best clinical response during 12- month follow- up after therapeutic human 









3- months postvaccination 
biopsy analyzed
1 15.5 VIN3 + PR + +
3 3.0 VIN2 + CR + -*
6 8.0 VIN3 + PR + +
9 3.5 VIN3 + CR + +
10 4.0 VIN2 + PR + +
11 25.3 VIN3 + NR + +
14 0.3 VIN3 + CR + +
15 2.0 VIN2 + NR + +
18 2.0 VaIN3 + NR + +
19 4.5 VIN3 + NR + +
20 2.0 VIN2 + PR + +
21 6.5 VIN3 + NR + –
22 2.0 VIN3 + NR + +
24 6.2 VIN3 + NR + +
26 1.0 VIN2 + NR + +
28 9.5 VIN3 + NR + +
29 4.2 VIN2 + PR + +
30 10.3 VIN3 + PR + –
32 1.5 VIN3 + CR + -*
51 19.0 VIN2 + NR + +
52 120.0 VIN3 + NR + +
53 42.0 VIN3 + PR + +
55 104.0 VIN3 + PR + +
57 3.0 VIN3 + NR + +
58 44.0 VIN3 + CR + -*
59 8.0 VIN3 + NR + +
61 12.0 VIN3 + CR + +
62 3.0 VaIN3 + PR + +
63 3.0 VIN3 + PR + +
The data were extracted from our previous report.21
*Vulvar high- grade squamous intraepithelial lesion (vHSIL) already cleared in biopsy.
CR, complete response (100% lesion clearance); NR, no response (<50% lesion size reduction); PR, partial response (≥50% lesion size 
reduction).
and for one patient with NR and one patient with PR of 
whom no postvaccination biopsy material was available. 
Consequently, we were able to analyze the postvaccina-
tion biopsies of 11 patients with NR, 9 patients with PR 
and 4 patients with CR in the same manner as the prevac-
cination biopsies were analyzed. This revealed a strong 
increase in the number of CD3+CD8−Tbet+ Th cells and 
a decrease in Tregs (figure 3B,C, online supplementary 
file 9), as well as a marked increase in CD14+ inflamma-
tory myeloid cells and decreased numbers of M2 macro-
phages (figure 3B,C, online supplementary file 9) in the 
vHSILs of patients with a PR or CR after vaccination. 
Notably, not only was the number of CD14+ inflammatory 
myeloid cells increased, but also the proportion of CD14+ 
cells expressing HLA- DR (online supplementary file 7), 
suggesting that these cells provide local help to the acti-
vation of the Th1 response. While the vHSILs of patients 
with NR displayed only minor changes in these subsets 
(figure 3B,C, online supplementary file 9), vaccination 
improved the coordinated immune infiltration of T cells 
and CD14+ myeloid cells in patients with PR (figure 4). 
Last but not least, whereas the vHSIL of patients with CR 
displayed both intraepithelial and stromal CD8+ T cell 
infiltration after vaccination, similar to what is seen in 
healthy vulvar tissue, the vHSIL of patients with PR did 
not (figure 3B,C). Notably, 2 out of 3 patients with CR 
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Figure 3 The tumor microenvironment of complete responders (CR, n=7) displays a similar immune infiltration pattern as 
found in healthy vulvar tissue. The numbers of intraepithelial and stroma- infiltrating T cell and myeloid cell subtypes, of which 
the median cell count exceeded the threshold of ≥10 cells/mm2, are presented as cells/mm2 in the (A) prevaccination (n=29) 
and (B) postvaccination (n=24) vulvar high- grade squamous intraepithelial lesion biopsies of vaccinated patients grouped 
according to their best clinical response during the 12 months of follow- up, and compared with healthy vulvar tissue (n=27). 
NR, non- responders (n=12); PR, partial responders (n=10). Statistical differences in the cell types between patient groups are 
depicted in online supplementary files 6 and 9. (C) Highlighted T cell and myeloid cell subtypes that significantly differed among 
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Figure 4 Correlation between the absolute numbers of tissue- infiltrating T cells and myeloid cells in the pretreatment and 
post- treatment vulvar high- grade squamous intraepithelial lesion (vHSIL) biopsies and in healthy vulvar tissue. Non- parametric 
Spearman r correlation analysis (two tailed) was performed to analyze the coinfiltration of the indicated different immune 
cell subtypes in the epithelium (E) and stroma (S) and is shown in a heatmap for healthy vulvar tissue (n=27), prevaccination 
complete responder patients with vHSIL (n=7) and partial responder patients with vHSIL (n=10) as well as postvaccination 
partial responder patients with vHSIL (n=9).
who could not be analyzed because their vHSIL disap-
peared within 3- month follow- up already displayed high 
numbers of Tbet+ Th cells (79, respectively, 460 cells/
mm2 stroma), CD8+ T cells (44, respectively, 107 cells/
mm2 stroma), and CD14+ inflammatory myeloid cells 
(316, respectively, 546 cells/mm2 stroma).
We have previously shown that patients with a CR 
displayed an overall stronger systemic interferon γ (IFNγ)- 
associated proliferative response after vaccination,21 and 
this was also observed after two or four vaccinations in the 
currently selected cohort when the average production 
of IFNγ to all peptide pools of all patients in the groups 
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was compared (figure 5A), and when the average IFNγ 
production was depicted as the median of the maximal 
IFNγ production after either two or four vaccinations to 
all six E6 and E7 peptide pools per patient (figure 5B). In 
order to understand the relative differences in immune 
infiltration and vaccine- induced T cell response between 
patients with NR, PR and CR, we z- transformed the data of 
those immune cell types of which the counts significantly 
differed between the patient groups either prevaccination 
or postvaccination, as well as that of the vaccine- specific 
IFNγ production (figure 5C,D). This revealed a propen-
sity of clinical responders to have pre- existing stromal 
infiltration with CD4+ T cells (CD3+CD8−) and CD14+ 
inflammatory myeloid cells. Furthermore, it suggests 
that in case a CD14+ inflammatory myeloid cell infiltra-
tion is already present a strong vaccine- induced immune 
response is not required (figure 5C). This profile was 
even more clear after vaccination, where clinical respon-
siveness was clearly correlated with the intraepithelial 
and stromal presence of type 1 CD4+ T cells (CD3+C-
D8−Tbet+) and CD14+ inflammatory myeloid cells lacking 
the expression of CD163 as well as the relative absence 
of Tregs (figure 5D). The absence of such a coordinated 
response before vaccination and the failure to alter this 
by vaccination explain why some of the patients with a 
strong vaccine- induced T cell response still displayed an 
NR. Thus, a generally strong and coordinated immune 
infiltration present already before or after vaccination in 
the TME by type 1 CD4+ T cells and CD14+ inflammatory 
myeloid cells was associated with a better clinical response 
to vaccination.
dIsCussIon
Our aim was to investigate if the immunological makeup 
of HPV16- induced vHSIL was of influence on the clinical 
response of patients to an HPV16 SLP vaccine, shown to 
be active in two separate trials.19 21 Our study is the first to 
show that a coordinated immune infiltration by activated 
type 1 CD8+ and T helper cells as well as HLA- DR+CD14+ 
myeloid cells is associated with a complete regression of 
vHSIL after vaccination. In a previous study, no differ-
ence was found in the numbers of pretreatment vHSIL- 
infiltrating CD4+ and CD8+ T cells between patients with 
or without a complete clinical response after vaccination 
with an HPV16- E6E7L2 fusion protein vaccine.29 This 
can be explained by the fact that these patients were 
pretreated with imiquimod,29 which is known to induce 
strong local inflammation30 that is reflected by infiltration 
with CD4+ and CD8+ T cells, activated DCs and macro-
phages,31 thereby recreating the desired immune micro-
environment. But also because no functional assessment 
of the infiltrating T cells was performed, while our data 
clearly point at the role of CD4+ Tbet+ (type 1) Th cells. 
An impact of the pre- existing immune microenvironment 
on clinical outcome was also not found in patients with 
cervical HSIL vaccinated with the HPV16/18 vaccine 
VGX-3100, but here only the number of CD8+ T cells and 
Tregs was assessed25 whereas it is known that also CD14+ 
inflammatory myeloid cells are associated with better 
prognosis in cervical cancer17 and as such are likely to play 
a similar role in its precursors. A coordinated response of 
T cells and inflammatory myeloid cells was also found to 
be required for the regression of tumors in the HPV16- 
positive tumor mouse models TC-1 and C3.32 Last but not 
least, we used software that performed automatic tissue 
segmentation and cell phenotyping, enabling the analysis 
of the entire tissue slide thereby precluding selection bias 
of analyzed areas, and also preventing potential interob-
server variation.
Our analyses revealed that the pre- existing vHSIL- 
immune infiltrate of CR resembled that found in healthy 
vulvar tissue, whereas the immune infiltrate in vHSIL 
of patients with PR and NR clearly differed. The vHSIL 
of patients with NR showed an overall low immune cell 
infiltration except for Tregs which were most abundant 
in this patient group, indicating that these lesions lacked 
inflammation and were immune suppressed; hence, they 
can be branded as relatively immune deserted/immu-
nosuppressed.10 Since healthy vulvar tissue comprises 
an actively inflamed immune microenvironment, the 
absence of it in the TME of NR must be labeled as aber-
rant. The underlying mechanism for this is currently 
unknown but potentially the answer can be found in the 
genomic instability of the lesions, which is often found 
on top of the expression of the HPV16 oncoproteins,33–35 
and has been related to immune evasion and reduced 
response to immunotherapy.36 Analyses of the postvacci-
nation samples at 3 months of follow- up made it clear that 
therapeutic vaccination was incapable of overcoming the 
‘cold’ local microenvironment that is present in NR. The 
intrinsic or extrinsic escape mechanism underlying this 
incapacity to attract immune effector cells is part of future 
studies. While the vHSIL of PR generally was infiltrated 
more densely with immune cells, a correlation analysis 
of the pre- existing immune cell infiltrate revealed that 
there was either no or a negative correlation between the 
numbers of vHSIL- infiltrating T cells and myeloid cells 
in this PR group. Some of them were relatively strongly 
infiltrated with T cells, a phenotype previously found to 
be correlated with partial responses of vHSIL after vacci-
nation,37 whereas others displayed relatively high levels of 
myeloid cells only. After vaccination, strong increases in 
both type 1 Th cells and HLA class II- positive inflamma-
tory macrophages were observed in the vHSIL of patients 
with a PR or CR at 12 months of follow- up. This coin-
cided with lower numbers of Tregs and M2 macrophages. 
Hence, therapeutic vaccination can incite and modulate 
inflamed lesions so that the immune infiltration becomes 
more coordinated and the effector cells increase to similar 
or higher numbers when compared with healthy vulvar 
tissue. In this aspect, it does not differ from other T cell- 
based approaches, including adoptive T cell transfer38 
and checkpoint blockade10 39 all of which have the best 
possible clinical impact when a tumor is inflamed or hot 
before start of therapy. The HPV16 SLP vaccine did not 
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Figure 5 Immune profile of non- responders (NR), partial responders (PR) and complete responders (CR) bases on the relative 
infiltration of significantly different immune cell subtypes and human papillomavirus (HPV)- specific T cell reactivity. The strength 
of the vaccine- induced HPV16- specific T cell response present in peripheral blood mononuclear cells (PBMC) as measured by 
the production of interferon γ (IFNγ) in the supernatant of PBMC stimulated with six different E6 and E7 peptide pools for clinical 
NR, PR and CR as determined previously by cytokine bead array20 is depicted as (A) the mean±SEM of all patients to all six 
peptide pools tested, before and after two and four vaccinations; and (B) the median of max calculated by taking the median of 
the highest responses to each peptide pool after two or four vaccinations. Shown is the mean±SEM of all medians per group. 
(C) and (D) The cell counts of all immune subsets of which the median cell count exceeded the threshold of ≥10 cells/mm2 and 
the numbers significantly differed between at least two of the patient groups (NR, PR, CR) either before vaccination (C) or after 
vaccination (D) as well as the median of max of IFNγ production as determined by cytometric bead array are depicted after the 
data were z- transformed to enable comparison of relative differences.
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increase the numbers of vHSIL- infiltrating CD8+ T cells, 
which were present already in the vHSIL that became a 
CR but not in vHSIL ending up as PR.
Finally, several trials with therapeutic vaccines against 
HPV- induced HSIL lesions have reported overall high 
immunogenicity of the vaccine but complete clinical 
responses in only part of the treated subjects.19–22 29 37 40 
The data of this study suggest that the HSIL microenvi-
ronment has an impact on the vaccine- induced clinical 
outcome and as such calls for the prospective valida-
tion of the combination of CD4+ cells, Tbet+ cells and 
CD14+ myeloid cells as predictive biomarkers for clin-
ical response of HSIL to therapeutic vaccination. These 
biomarkers can easily be applied in routine diagnostics, as 
they only require routinely taken FFPE tissue and regular 
single immunohistochemical stainings. The combination 
of multiple biomarkers is likely to increase the sensitivity 
of the prediction tool.41 Furthermore, our data strongly 
suggest that the efficacy of therapeutic vaccines in this 
patient group can be increased when it is combined with 
other drugs that induce local acute inflammation, to 
support the infiltration of vaccine- activated T cells and 
inflammatory myeloid cells. Hence, our findings show 
that the current paradigm of personalized cancer immu-
notherapy also applies to therapeutic vaccines for the 
treatment of patients with virally induced lesions as well 
as provides a foundation for future combination therapy 
studies.
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